MBX Biosciences (MBX) Competitors $10.49 +0.62 (+6.28%) Closing price 04/30/2025 04:00 PM EasternExtended Trading$10.26 -0.23 (-2.19%) As of 07:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock MBX vs. CALT, IOVA, AMPH, SNDX, ADPT, BGM, AUPH, EVO, ETNB, and WVEShould you be buying MBX Biosciences stock or one of its competitors? The main competitors of MBX Biosciences include Calliditas Therapeutics AB (publ) (CALT), Iovance Biotherapeutics (IOVA), Amphastar Pharmaceuticals (AMPH), Syndax Pharmaceuticals (SNDX), Adaptive Biotechnologies (ADPT), Qilian International Holding Group (BGM), Aurinia Pharmaceuticals (AUPH), Evotec (EVO), 89bio (ETNB), and Wave Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry. MBX Biosciences vs. Calliditas Therapeutics AB (publ) Iovance Biotherapeutics Amphastar Pharmaceuticals Syndax Pharmaceuticals Adaptive Biotechnologies Qilian International Holding Group Aurinia Pharmaceuticals Evotec 89bio Wave Life Sciences Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and MBX Biosciences (NYSE:MBX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, community ranking, earnings, profitability, dividends, valuation, institutional ownership and media sentiment. Do analysts prefer CALT or MBX? Calliditas Therapeutics AB (publ) presently has a consensus price target of $39.25, indicating a potential downside of 1.88%. MBX Biosciences has a consensus price target of $37.50, indicating a potential upside of 257.48%. Given MBX Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe MBX Biosciences is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation & earnings, CALT or MBX? MBX Biosciences has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62MBX BiosciencesN/AN/AN/AN/AN/A Does the MarketBeat Community believe in CALT or MBX? Calliditas Therapeutics AB (publ) received 20 more outperform votes than MBX Biosciences when rated by MarketBeat users. However, 100.00% of users gave MBX Biosciences an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformCalliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% MBX BiosciencesOutperform Votes7100.00% Underperform VotesNo Votes Is CALT or MBX more profitable? MBX Biosciences has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. MBX Biosciences' return on equity of 0.00% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% MBX Biosciences N/A N/A N/A Does the media prefer CALT or MBX? In the previous week, MBX Biosciences had 1 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 1 mentions for MBX Biosciences and 0 mentions for Calliditas Therapeutics AB (publ). MBX Biosciences' average media sentiment score of 1.76 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral MBX Biosciences Very Positive Do insiders and institutionals hold more shares of CALT or MBX? 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryMBX Biosciences beats Calliditas Therapeutics AB (publ) on 9 of the 13 factors compared between the two stocks. Get MBX Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBX vs. The Competition Export to ExcelMetricMBX BiosciencesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$350.62M$6.89B$5.56B$18.97BDividend YieldN/A3.05%5.11%4.02%P/E RatioN/A7.4422.4832.71Price / SalesN/A242.70395.9327.84Price / CashN/A65.8538.1817.53Price / BookN/A6.516.774.47Net IncomeN/A$143.21M$3.22B$1.02B7 Day Performance13.16%1.98%1.47%0.50%1 Month Performance52.92%6.89%3.99%-2.83%1 Year PerformanceN/A-2.52%16.15%4.36% MBX Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBXMBX Biosciences2.5913 of 5 stars$10.49+6.3%$37.50+257.5%N/A$350.62MN/A0.0036CALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180IOVAIovance Biotherapeutics4.564 of 5 stars$3.61+2.8%$18.22+404.8%-69.5%$1.18B$164.07M-2.42500Upcoming EarningsGap DownAMPHAmphastar Pharmaceuticals4.5062 of 5 stars$24.41+0.9%$43.50+78.2%-40.8%$1.16B$731.97M8.141,620Upcoming EarningsPositive NewsSNDXSyndax Pharmaceuticals3.6294 of 5 stars$13.42+0.7%$36.20+169.7%-33.0%$1.15B$23.68M-3.70110Upcoming EarningsPositive NewsADPTAdaptive Biotechnologies4.1411 of 5 stars$7.77-1.6%$9.40+21.0%+180.9%$1.15B$178.96M-7.13790News CoveragePositive NewsGap DownBGMQilian International Holding GroupN/A$11.27+1.6%N/AN/A$1.10B$25.10M0.00298AUPHAurinia Pharmaceuticals2.6458 of 5 stars$8.00-2.2%$11.50+43.8%+61.9%$1.09B$235.13M-53.33300Positive NewsEVOEvotec1.8628 of 5 stars$4.30+1.9%$5.93+38.0%-19.1%$1.09B$796.97M0.004,200Upcoming EarningsShort Interest ↓Gap DownETNB89bio2.7852 of 5 stars$7.40+6.6%$27.25+268.2%-5.8%$1.08BN/A-2.5440Upcoming EarningsAnalyst UpgradeNews CoveragePositive NewsWVEWave Life Sciences4.313 of 5 stars$6.83+1.5%$22.18+224.8%+56.6%$1.05B$108.30M-6.15240Upcoming EarningsAnalyst ForecastNews CoveragePositive News Related Companies and Tools Related Companies Calliditas Therapeutics AB (publ) Competitors Iovance Biotherapeutics Competitors Amphastar Pharmaceuticals Competitors Syndax Pharmaceuticals Competitors Adaptive Biotechnologies Competitors Qilian International Holding Group Competitors Aurinia Pharmaceuticals Competitors Evotec Competitors 89bio Competitors Wave Life Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MBX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MBX Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MBX Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MBX Stock Free MBX Stock Alerts